申请人:HEBEI GRANDIOS PHARMA CO., LTD.
公开号:US11046687B2
公开(公告)日:2021-06-29
A novel polycyclic amide compound, preparation process and use thereof are provided. The compound has cytotoxic biological activity, particularly for the treatment and/or prevention of cell proliferative diseases such as cancer. This compound is a compound represented by Formula I or
a pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture, prodrug and N-oxide thereof, wherein, R, R1-R3 are independently selected from hydrogen, C1-5 alkyl, or C1-5 having a hydroxyl group or a halogen, and may be bonded to each other to form a ring, Z is an arbitrary substituent group, X1 and X2 may be carbon or nitrogen respectively, Q is oxygen or sulfur. Compared to the existing known polycyclic amide compounds, the novel polycyclic amide compound has more potent cytotoxicity and can be used for the treatment of diseases such as tumors, cancers, Alzheimer's disease, autoimmune diseases, cataracts, psychological disorders, depression and/or anxiety.
本研究提供了一种新型多环酰胺化合物及其制备工艺和用途。该化合物具有细胞毒性生物活性,尤其适用于治疗和/或预防癌症等细胞增殖性疾病。该化合物是由式 I 或
一种药学上可接受的盐、溶液剂、多晶型、对映体或外消旋混合物、原药及其N-氧化物,其中,R、R1-R3独立选自氢、C1-5烷基或具有羟基或卤素的C1-5,并可相互键合形成环,Z为任意取代基,X1和X2可分别为碳或氮,Q为氧或硫。与现有已知的多环酰胺化合物相比,新型多环酰胺化合物具有更强的细胞毒性,可用于治疗肿瘤、癌症、阿尔茨海默病、自身免疫性疾病、白内障、心理障碍、抑郁症和/或焦虑症等疾病。